专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003072594A2 AN OBLIGATE DOMAIN-SWAPPED DIMER OF CYANOVIRIN WITH ENHANCED ANTI-VIRAL ACTIVITY 审中-公开
标题翻译：具有增强抗病毒活性的CYANOVIRIN的寡核苷酸转换二聚体
公开(公告)号：WO2003072594A2
公开(公告)日：2003-09-04
申请号：PCT/US2003/006115
申请日：2003-02-25
申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE , BEWLEY, Carole, A.
发明人： BEWLEY, Carole, A.
IPC分类号： C07K
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/53
摘要： A purified or isolated obligate domain-swapped dimer of CVN; an isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector; a host cell comprising such an isolated or purified nucleic acid; a composition comprising (i) the obligate domain-swapped dimer of CVN or the isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector, and (ii) a carrier therefor; a method of inhibiting a viral infection of a mammal, which method comprises administering to the mammal an antiviral effective amount of the aforementioned composition, whereupon the viral infection of the mammal is inhibited; and a method of making an obligate domain-swapped dimer of CVN, which method comprises introducing at least one mutation in the linker region of wild-type CVN, whereupon an obligate domain-swapped dimer of CVN is obtained.
摘要翻译：纯化或分离的CVN的专一性域交换的二聚体，其是编码CVN的至少一个专性域交换的二聚体的分离或纯化的核酸，任选以载体的形式，包含这种分离或纯化的核酸的宿主细胞包含我是CVN的专有域交换的二聚体或编码CVN的至少一个专性域交换的二聚体的分离的或纯化的核酸，任选地以载体的形式，和ii的载体用于抑制病毒感染的方法哺乳动物，该方法包括向哺乳动物施用抗病毒有效量的上述组合物，由此抑制哺乳动物的病毒感染，以及制备CVN的专性域交换的二聚体的方法，该方法包括将至少一种突变引入野生型CVN的接头区域，得到CVN的专有域交换的二聚体。

2. 发明申请

WO2003072594A3 AN OBLIGATE DOMAIN-SWAPPED DIMER OF CYANOVIRIN WITH ENHANCED ANTI-VIRAL ACTIVITY 审中-公开
公开(公告)号：WO2003072594A3
公开(公告)日：2003-09-04
申请号：PCT/US2003/006115
申请日：2003-02-25
申请人： GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE , BEWLEY, Carole, A.
发明人： BEWLEY, Carole, A.
IPC分类号： A61K39/21
摘要： A purified or isolated obligate domain-swapped dimer of CVN; an isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector; a host cell comprising such an isolated or purified nucleic acid; a composition comprising (i) the obligate domain-swapped dimer of CVN or the isolated or purified nucleic acid encoding at least one obligate domain-swapped dimer of CVN, optionally in the form of a vector, and (ii) a carrier therefor; a method of inhibiting a viral infection of a mammal, which method comprises administering to the mammal an antiviral effective amount of the aforementioned composition, whereupon the viral infection of the mammal is inhibited; and a method of making an obligate domain-swapped dimer of CVN, which method comprises introducing at least one mutation in the linker region of wild-type CVN, whereupon an obligate domain-swapped dimer of CVN is obtained.

3. 发明申请

WO2005087799A2 MVL, AN ANTIVIRAL PROTEIN FROM A CYANOBACTERIUM 审中-公开
标题翻译： MVL，来自CYANOBACTERIUM的抗病毒蛋白质
公开(公告)号：WO2005087799A2
公开(公告)日：2005-09-22
申请号：PCT/US2005/007703
申请日：2005-03-09
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , BEWLEY, Carole, A.
发明人： BEWLEY, Carole, A.
IPC分类号： C07K9/00
CPC分类号： C07K14/195 , Y10S530/825
摘要： The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1→6)Man-beta (1→4) G1cNAc-beta(1→4)G1cNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.
摘要翻译：本发明涉及例如与来自蓝细菌的微囊藻（Microcystis viridis）分离的多肽，其与包含四糖Man-α-（1-> 6）Man-β（1-> 4）G1cNAc-β（ 1-> 4）G1cNAc。多肽可以例如从表达编码MVL样多肽的重组核酸的细胞获得。本发明还涉及包含序列GPLWSNXEAQXXGPX（SEQ ID NO：1）和/或序列FTGQWXTXVEXXMSV（SEQ ID NO：2）的一个或多个拷贝的一个或多个拷贝的分离的多肽，其中所述多肽特异性结合于上述寡糖。还公开了包含此类多肽和效应分子的缀合物，以及使用此类多肽或缀合物的方法，例如用于抑制病毒如HIV的感染或从样品中除去病毒如HIV。作为体液或无生命物体。

4. 发明申请

WO2002081483A3 INHIBITORS OF ACYL GLUCOSAMINYL INOSITOL AMIDASE AND METHODS OF USE 审中-公开
公开(公告)号：WO2002081483A3
公开(公告)日：2002-10-17
申请号：PCT/US2002/011117
申请日：2002-04-08
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , FAHEY, Robert, C. , NEWTON, Gerald, L. , BEWLEY, Carole, A. , NICHOLAS, Gillian
发明人： FAHEY, Robert, C. , NEWTON, Gerald, L. , BEWLEY, Carole, A. , NICHOLAS, Gillian
IPC分类号： A61K31/165
摘要： The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention compounds are naturally occurring compounds obtained from marine sponges and other organisms. The invention further provides methods for using the compounds to inhibit virulence and reduce antibiotic resistance of mycothiol-producing bacteria.

5. 发明申请

WO2011106630A3 CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN 审中-公开
标题翻译： CHRYSOPHAENTIN抗微生物化合物抑制FTSZ蛋白
公开(公告)号：WO2011106630A3
公开(公告)日：2011-09-01
申请号：PCT/US2011/026220
申请日：2011-02-25
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES , BEWLEY, Carole, A. , PLAZA, Alberto , KEFFER, Jessica
发明人： BEWLEY, Carole, A. , PLAZA, Alberto , KEFFER, Jessica
IPC分类号： C07C15/50 , C07C15/40
摘要： Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from Chrysophaeum taylori. Certain embodiments of the chrysophaentin compounds inhibit FtsZ protein, thereby inhibiting the growth of clinically relevant bacteria, including drug-resistant strains.
摘要翻译：公开了抗微生物菊苣仁苷化合物，包含该菊苣仁苷化合物的药物组合物以及使用该菊苣仁苷化合物的方法的实施方案。公开的化合物的一些实施方案是从Chrysophaeum taylori分离的。长春花碱化合物的某些实施方案抑制FtsZ蛋白，从而抑制临床相关细菌（包括耐药菌株）的生长。

6. 发明申请

WO2008098138A1 SYNTHETIC MACROCYCLIC COMPOUNDS FOR TREATING CANCER 审中-公开
标题翻译：用于治疗癌症的合成大环化合物
公开(公告)号：WO2008098138A1
公开(公告)日：2008-08-14
申请号：PCT/US2008/053334
申请日：2008-02-07
申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , BEWLEY, Carole, A. , METAFERIA, Belhu, B.
发明人： BEWLEY, Carole, A. , METAFERIA, Belhu, B.
IPC分类号： C07D267/00 , A61K31/395 , A61P35/00
CPC分类号： C07D267/00
摘要： Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is O or 1; R 1 , R 2 and R 3 independently are H, aralkyl, acyl, lower alkyl or silyl; X is -C(O)N(R 4 )- or -C(S)N(R 4 )-; -C(O)-; -C(S)-; Y is -OC(O)-; -OC(O)N(R 5 )-; -N(R 5 )C(0)-; or -OC(O)O-; G comprises a saturated or unsaturated aliphatic chain having from 2 to about 10 atoms in the chain, the chain optionally including 1, 2, or 3 heteroatoms; the chain optionally being substituted with 1, 2 or 3 substituents independently selected from lower alkyl, -OR 6 , epoxy, aziridinyl, cyclopropyl, -NR 7 R 8 and halo; R 4 , R 5 , R 6 , R 7 and R 8 independently are selected from H, lower alkyl and acyl. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions including one or more of the disclosed macrocycles.
摘要翻译：本文公开了有效抑制细胞迁移的大环化合物。在一个实施方案中，所述化合物具有以下结构：或其任何药学上可接受的盐或溶剂合物，其中：m为O或1; R 1，R 2和R 3独立地是H，芳烷基，酰基，低级烷基或甲硅烷基; X是-C（O）N（R 4） - 或-C（S）N（R 4） - ; -C（O） - ; -C（S） - ; Y为-OC（O） - ; -OC（O）N（R ^{5 ） - ; -N（R ^{5 ）C（O） - ; 或-OC（O）O-; G包含在链中具有2至约10个原子的饱和或不饱和脂族链，该链任选地包括1,2或3个杂原子; 该链任选被1,2或3个独立地选自低级烷基，-OR 6，环氧基，氮丙啶基，环丙基，-NR 7 R 8的取代基取代和光环; R 4，R 5，R 6，R 7和R 8独立地是选自H，低级烷基和酰基。还公开了制备和使用化合物的方法以及包含一种或多种所公开的大环化合物的药物组合物。}}

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式